Comparative Pharmacology
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFATRIM SS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFATRIM SS.
SODIUM SULFACETAMIDE vs SULFATRIM-SS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking the synthesis of folic acid and ultimately nucleic acid synthesis, leading to bacteriostatic activity.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. Sequential blockade produces bactericidal synergy.
1-2 drops of 10% or 30% solution into conjunctival sac every 2-3 hours during waking hours for 7-10 days.
1 double-strength tablet (160 mg trimethoprim / 800 mg sulfamethoxazole) orally every 12 hours for 10-14 days.
None Documented
None Documented
7-12 hours in normal renal function; prolonged to 20-50 hours in renal impairment.
SMX: 9-12 hours (increased in renal impairment); TMP: 8-11 hours (increased in renal impairment); both prolonged in elderly.
Renal: 85-100% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Renal excretion of unchanged sulfamethoxazole (SMX) approximately 20%, trimethoprim (TMP) approximately 60%; biliary/fecal elimination minor (SMX <5%, TMP <10%).
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic